ArticleFrontiers in pharmacology2026
The cost effectiveness of toripalimab plus bevacizumab versus sorafenib for the first-line treatment of advanced hepatocellular carcinoma in China.
Ling Ma et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.